舒尼替尼标准 vs. 调整剂量方案治疗转移性肾细胞癌:来自大型回顾性分析的结果
Background
There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patients aged ≥ 70 years.
Patients and Methods
We reviewed the clinical files of 185 patients aged >70 years with mRCC treated with first-line sunitinib in seventeen Italian Oncology Units from February 2006 to September 2011. One hundread twenty-three patients (66.5%) received a standard 50 mg/d 4 wk on/2 wk off regimen (SR), and 62 patients (33.5%) received an adapted regimen (AR) consisting in 37.5 mg/d 4 wk on/2 wk off in 67.7% of cases.
Results
Median age was 74 years. Patients treated with an AR were older than those treated with the SR (P <.0001). In the overall population, the median progression-free survival (PFS) was 11 months, and the median overall survival (OS) was 25.5 months. Grade 3-4 toxicities occurred in 70.7% of SR and 51.6% of AR, respectively; dose reductions were required in 66.7% and 41.9%, respectively; discontinuations due to therapy-related adverse events occurred in 20.3% and 24.2%, respectively. In multivariate analysis, only performance status and the Heng score were predictors of either PFS or OS.
Conclusions
Sunitinib is active and feasible in elderly patients with mRCC. A sunitinib AR could be considered as an option in selected older mRCC patients. The optimal treatment of frail patients with mRCC remains to be established.
主要结论:对于老年转移性肾细胞患者,舒尼替尼治疗可行,有效。调整剂量方案可被用于经选择的老年转移性肾细胞癌患者中。
上一篇: 氨甲蝶呤联合英夫利西单抗的效果不优于英夫利西单抗单药治疗克罗恩病
下一篇: 依维莫司联合依西美坦 vs. 依西美坦单药治疗老年HER2阴性、激素受体阳性乳腺癌患者的疗效和安全性对比:来自BOLERO-2研究的结果
- 您可能感兴趣的文章
-